Leadership & Pay ·
Madrigal Pharmaceuticals expanded its Board from eight to nine members and elected John C. Reed, M.D., Ph.D., as a…
MDGLMadrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals expanded its Board from eight to nine members and elected John C. Reed, M.D., Ph.D., as a Class II director effective August 11, 2026. Dr. Reed, currently Executive Vice President of Innovative Medicine at Johnson & Johnson, will serve on the Science and Technology Committee. His compensation includes a $50,000 annual cash retainer, a $10,000 committee fee, and a $675,000 equity grant split between stock options and restricted stock units with standard vesting schedules. Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).